Surgery Partners beats Q2 revenue estimates, reaffirms guidance

Surgery Partners

05/08/2025 12:42

Overview

Surgery Partners Q2 revenue rises 8.4%, beating analysts' expectations, per LSEG data

Adjusted EPS for Q2 beats consensus

Adjusted EBITDA for Q2 grows 9% and exceeds analysts' estimates

Outlook

Surgery Partners reaffirms 2025 revenue guidance of $3.30 bln to $3.45 bln

Company expects 2025 Adjusted EBITDA between $555 mln and $565 mln

Company optimistic on surgical trends and regulatory landscape

Surgery Partners focuses on portfolio optimization for leverage reduction

Result Drivers

OPERATIONAL STRATEGY - Co attributes revenue growth to strong operational strategy and momentum in ambulatory surgery industry, per CEO Eric Evans

SAME-FACILITY PERFORMANCE - Increase in same-facility revenues and cases contributed to overall revenue growth

ACQUISITION BENEFITS - Integration benefits from recent acquisitions supported margin expansion, per CFO Dave Doherty

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$826.20 mln
$817 mln (12 Analysts)
Q2 Adjusted EPS
Beat
$0.17
$0.13 (12 Analysts)
Q2 Adjusted EBITDA
Beat
$129 mln
$128.30 mln (11 Analysts)
Q2 Adjusted EBITDA Margin
15.6%
Q2 Operating Income
$111.70 mln
Q2 Pretax Profit
$43.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Surgery Partners Inc is $33.00, about 32.7% above its August 4 closing price of $22.22

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nGNX7DXfhm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)